University of Houston College of Pharmacy, 1441 Moursund Street, Houston, TX 77030, USA.
Expert Rev Pharmacoecon Outcomes Res. 2010 Aug;10(4):441-51. doi: 10.1586/erp.10.49.
Rates of antibiotic resistance in Pseudomonas aeruginosa are increasing worldwide. The multidrug-resistant (MDR) phenotype in P. aeruginosa could be mediated by several mechanisms including multidrug efflux systems, enzyme production, outer membrane protein (porin) loss and target mutations. Currently, no international consensus on the definition of multidrug resistance exists, making direct comparison of the literature difficult. Inappropriate empirical therapy has been associated with increased mortality in P. aeruginosa infections; delays in starting appropriate therapy may contribute to increased length of hospital stay and persistence of infection. In addition, worse clinical outcomes may be associated with MDR infections owing to limited effective antimicrobial options. This article aims to summarize the contemporary literature on patient outcomes following infections caused by drug-resistant P. aeruginosa. The impact of antimicrobial therapy on patient outcomes, mortality and morbidity; and the economic impact of MDR P. aeruginosa infections will be examined.
铜绿假单胞菌的抗生素耐药率在全球范围内呈上升趋势。铜绿假单胞菌的多药耐药（MDR）表型可能由多种机制介导，包括多药外排系统、酶的产生、外膜蛋白（孔蛋白）缺失和靶基因突变。目前，对于多药耐药的定义尚无国际共识，使得文献的直接比较变得困难。不适当的经验性治疗与铜绿假单胞菌感染的死亡率增加有关；开始适当治疗的延迟可能导致住院时间延长和感染持续存在。此外，由于有效的抗菌药物选择有限，MDR 感染可能导致更差的临床结局。本文旨在总结有关耐药铜绿假单胞菌感染患者结局的当代文献。将检查抗菌治疗对患者结局、死亡率和发病率的影响，以及 MDR 铜绿假单胞菌感染的经济影响。
